Contribution of catechol-O-methyltransferase Val158Met polymorphism to endometrial cancer risk in postmenopausal women: A meta-analysis

Genetics and Molecular Research

Volumn 12, Issue 4, 2013, Pages 6442-6453

  Lin, G ^a   Zhao, J ^b   Wu, J ^b   Andreevich O , R ^a   Zhang, W H ^b   Zhang, Y ^b,c   Yu, L ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

COMT; Endometrial cancer; Meta analysis; Polymorphism

Indexed keywords

AMINO ACID SUBSTITUTION; CATECHOL O-METHYLTRANSFERASE; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE;

EID: 84890398599     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2013.December.10.5     Document Type: Article

References (31)

1. Ball P, Knuppen R, Haupt M and Breuer H (1972). Interactions between estrogens and catechol amines. 3. Studies on the methylation of catechol estrogens, catechol amines and other catechols by the ctechol-O-methyltransferases of human liver. J. Clin. Endocrinol. Metab. 34: 736-746.
2. Begg CB and Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
3. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, et al. (1997). Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. U. S. A. 94: 10937-10942.
4. Dawling S, Roodi N, Mernaugh RL, Wang X, et al. (2001). Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Canc. Res. 61: 6716-6722.
5. DerSimonian R and Laird N (1986). Meta-analysis in clinical trials. Control Clin. Trials 7: 177-188.
6. Doherty JA, Weiss NS, Freeman RJ, Dightman DA, et al. (2005). Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Canc. Epidemiol. Biomarkers Prev. 14: 357-366.
7. Egger M, Davey SG, Schneider M and Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
8. He XF, Wei W, Li SX, Su J, et al. (2012). Association between the COMT Val158Met polymorphism and breast cancer risk: a meta-analysis of 30,199 cases and 38,922 controls. Mol. Biol. Rep. 39: 6811-6823.
9. Higgins JP, Thompson SG, Deeks JJ and Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
10. Hirata H, Hinoda Y, Okayama N, Suehiro Y, et al. (2008a). COMT polymorphisms affecting protein expression are risk factors for endometrial cancer. Mol. Carcinog. 47: 768-774.
11. Hirata H, Hinoda Y, Okayama N, Suehiro Y, et al. (2008b). CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 112: 1964-1973.
12. Huber JC, Schneeberger C and Tempfer CB (2002). Genetic modelling of the estrogen metabolism as a risk factor of hormone-dependent disorders. Maturitas 41 (Suppl 1): S55-S64.
13. Jiang DK, Ren WH, Yao L, Wang WZ, et al. (2010). Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk. Urology 76: 765-767.
14. Kushner PJ, Agard DA, Greene GL, Scanlan TS, et al. (2000). Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74: 311-317.
15. Li L, Li FX, Zhang N and Du YF (2010). Association of gene polymorphism in cytochrome P450 1B1 and COMT, with the expression of mRNA and susceptibility to endometrial cancer in Chinese. J. Hebei Med. Univ. 31: 1433-1437.
16. Liu J, Yang XS, Qu X and Li H (2007). Relation among single nucleotide metablolizing genes CYPl7, COMT and endometrial adenocarcinoma risk in Chinese. J. Shandong Univ. 45: 18-21.
17. Lundstrom K, Tenhunen J, Tilgmann C, Karhunen T, et al. (1995). Cloning, expression and structure of catechol-O-methyltransferase. Biochim. Biophys. Acta 1251: 1-10.
18. Mantel N and Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Canc. Inst. 22: 719-748.
19. McGrath M, Hankinson SE, Arbeitman L, Colditz GA, et al. (2004). Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis 25: 559-565.
20. Packer BR, Yeager M, Burdett L, Welch R, et al. (2006). SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res. 34: D617-D621.
21. Sorosky JI (2008). Endometrial cancer. Obstet. Gynecol. 111: 436-447.
22. Suzuki M, Kurosaki T, Arai T, Sawabe M, et al. (2007). The Val158Met polymorphism of the catechol-O-methyltransferase gene is not associated with the risk of sporadic or latent prostate cancer in Japanese men. Int. J. Urol. 14: 800-804.
23. Szyllo K, Smolarz B, Romanowicz-Makowska H, Przybylowska K, et al. (2007). The risk of endometrial cancer appearance and CYP19 and COMT gene polymorphism. Pol. Merkur. Lekarski 22: 208-210.
24. Tao MH, Cai Q, Xu WH, Kataoka N, et al. (2006). Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and endometrial cancer risk in Chinese women. Canc. Epidemiol. Biomarkers Prev. 15: 2570-2573.
25. Thompson PA, Shields PG, Freudenheim JL, Stone A, et al. (1998). Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Canc. Res. 58: 2107-2110.
26. Woolf B (1955). On estimating the relation between blood group and disease. Ann. Hum. Genet. 19:251-253.
27. Xie T, Ho SL and Ramsden D (1999). Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol. Pharmacol. 56: 31-38.
28. Zhao XM, Xie MQ, Yang DZ, Wang LA, et al. (2007). Polymorphism of catechol-O-methyltransferase gene in relation to the risk of endometrial cancer. Zhonghua Fu Chan Ke Za Zhi. 42: 116-119.
29. Zhu BT and Conney AH (1998a). Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19: 1-27.
30. Zhu BT and Conney AH (1998b). Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Canc. Res. 58: 2269-2277.
31. Zimarina TC, Kristensen VN, Imianitov EN and Bershtein LM (2004). Polymorphisms of CYP1B1 and COMT in breast and endometrial cancer. Mol. Biol. 38: 386-393.